Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Resectable Non-Small Cell Lung Cancer

Trial Identifier: D9108C00002
Sponsor: MedImmune, LLC
NCTID:: NCT03794544
Start Date: March 2019
Primary Completion Date: January 2021
Study Completion Date: January 2021
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
English version
French version
French version
German version
Italian version
Portuguese version
Spanish version
Spanish version

Trial Locations

Country Location
Canada, QC Montreal, QC, Canada, H4A 3J1
France Marseille Cedex 9, France, 13009
France Toulouse CEDEX 09, France, 31059
Italy Orbassano, Italy, 10043
Portugal Porto, Portugal, 4200-072
Spain A Coruña, Spain, 15001
Spain Barcelona, Spain, 08916
Switzerland Zurich, Switzerland, 8091
United States of America, CA La Jolla, CA, United States of America, 92093
United States of America, FL Fort Myers, FL, United States of America, 33901
United States of America, FL Leesburg, FL, United States of America, 34748
United States of America, MD Baltimore, MD, United States of America, 21231
United States of America, NY Buffalo, NY, United States of America, 14263
United States of America, NY New York, NY, United States of America, 10016
United States of America, TN Chattanooga, TN, United States of America, 37404
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, TX Houston, TX, United States of America, 77030
United States of America, VA Fairfax, VA, United States of America, 22031